%0 Journal Article %T FDG-PET/CT in Lymphoma: Where Do We Go Now? %+ Scintidoc Nuclear Medicine Center [Montpellier] (SNMC) %+ Nuclear Oncology (CRCINA-ÉQUIPE 13) %+ Centre hospitalier universitaire de Nantes (CHU Nantes) %+ Institut Claudius Regaud %+ Centre de Recherches en Cancérologie de Toulouse (CRCT) %A Al Tabaa, Yassine %A Bailly, Clement %A Kanoun, Salim %< avec comité de lecture %@ 2072-6694 %J Cancers %I MDPI %V 13 %N 20 %P 5222 %8 2021-10 %D 2021 %R 10.3390/cancers13205222 %M 34680370 %K Deauville 5PS %K FDG-PET %K lymphomas %Z Life Sciences [q-bio]/CancerJournal articles %X 18F-fluorodeoxyglucose positron emission tomography combined with computed tomography (FDG-PET/CT) is an essential part of the management of patients with lymphoma at staging and response evaluation. Efforts to standardize PET acquisition and reporting, including the 5-point Deauville scale, have enabled PET to become a surrogate for treatment success or failure in common lymphoma subtypes. This review summarizes the key clinical-trial evidence that supports PET-directed personalized approaches in lymphoma but also points out the potential place of innovative PET/CT metrics or new radiopharmaceuticals in the future. %G English %2 https://inserm.hal.science/inserm-03540811/document %2 https://inserm.hal.science/inserm-03540811/file/cancers-13-05222-v2.pdf %L inserm-03540811 %U https://inserm.hal.science/inserm-03540811 %~ INSERM %~ UNIV-NANTES %~ UNIV-TLSE3 %~ CNRS %~ UNIV-ANGERS %~ CRCINA %~ NANTES-UNIVERSITE %~ UNIV-NANTES-AV2022 %~ UNIV-UT3 %~ UT3-INP %~ UT3-TOULOUSEINP %~ CRCT